Leerink Partners Initiates Coverage On Oruka Therapeutics with Outperform Rating, Announces Price Target of $44
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $44.
September 17, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Oruka Therapeutics with an Outperform rating and a price target of $44, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $44 by Leerink Partners suggests a positive sentiment towards Oruka Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100